new angl redirect cell therapi
tritac initi buy target
forma cash includ up-front
rate amend licens agreement announc
novemb note harpoon end roughli
cash cash equival
gener data prior harpoon februari ipo
modular platform cusp clinic valid harpoon
advanc proprietari platform redirect cell therapi
tritac across solid tumor well multipl myeloma poc
data two wholly-own asset psma-target tritac
mesothelin-target tritac anticip
respect beyond program anticip
initi phase program abbvie-partn
rate anti-bcma tritac
plethora challeng address
cell dysfunct oncolog recent data across bispecif
encourag reflect year clinic experi elabor
upon subsequ solid tumor microenviron like present
uniqu challeng address harpoon modular redirect
cell therapi platform alon potenti synergist addit
combin exist therapeut modal view henc
readout meaning driver stock
trade ipo multipl
cash recent downturn vs
xbi appear discount near-term payment
potenti biobuck demonstr
tumor traffick adequ handl coupl relev
biomark data remain base case expect underli buy
rate target
tritac offer convent bite hla loss
heterozygos appear common immun evas strategi
employ tumor acquir resist checkpoint blockad
case associ hla down-regul
underli moa tritac independ mimic
cognat tcr/hla-peptid interact tritac bite achiev
cell activ artifici cluster tcr complex cell/
target cell synaps requir molecul induc target-
cell apoptosi explain picomolar potenc henc tritac might
provid therapeut hypothesi test overcom primari
acquir resist hla loss bite suffer
short half-lif tritac extend half-lif provid conveni
weekli dose paradigm without fc-mediat interact given
preclin potenc tritac much like bispecif may find
key role effect target tumor low neoantigen burden and/
low inflamm although drawn hematolog malign
blinatumomab rate flotetuzumab
express patient relapsed/refractori agent suggest
potenti synergi checkpoint inhibit furthermor
tritac superior tumor tissu penetr compar
bulkier mab- architectur construct allow potenti activ
tumor cocoon dens fibrou stroma exampl cancer
pancrea final tritac may induc intratumor accumul
cell perhap also promot activ expans tumor-
reactiv lymphocyt convert immunolog cold tumor
limit intratumor infiltr hot tumor contain larger
number activ cell
definit distribut analyst rate analyst certif disclosur pleas refer page report
offer promis potenc off-the-shelf flexibl gener tritac iter grow class
redirect cell therapi elicit antineoplast activ cross-link compon cell receptor
complex tumor-associ antigen surfac target cell psma-target tritac avail dose-
escal outcom psma-target bispecif point dose-depend serum reduct
durabl diseas control subject metastat castration-resist prostat cancer mcrpc hint potenti
viabil cell engag indic longer half-lif greater vitro activ appear
potent mous model compar caveat head-to-head comparison
importantli advanc half-lif extend version although elabor upon subsequ
former half-lif vs half-lif might doctor order poc data
potenti anticip would mark first clinic read tritac platform
could meaning driver harpoon share view beyond anti-tumor activ would expect clariti
tradit challeng impact redirect cell therapi includ manag implement
step-dos dexamethason suffici base induc substanti amelior
dexamethason step-dos clinic set preclin model mark impact
expans anti-drug antibodi ada led discontinu two peer cell engag note avail
disclosur harpoon indic ada detect almost year clinic experi
effect mcrpc tumor microenviron cell proliferation/exhaust neg impact
cell therapi set though could address combin checkpoint inhibitor eventu
importantli off-the-shelf avail abil repeat dose smaller size potenti deeper tumor penetr
emerg clinic data differenti bispecif cell view deeper
dive refer page
mesothelin-target tritac explor high-risk higher-reward indic mesothelin cell surfac
antigen highli express mesothelioma ovarian pancreat cancer approach target mesothelin
investig early-stag clinic trial includ immunotoxin vaccin chimer monoclon antibodi antibodi
drug conjug t-cell therapi howev much earli clinic trial data suggest ad immunosuppress
agent combin mesothelin-direct therapi chemotherapi immunotherapi may improv therapeut respons
purpos cell target membrane-bound version msln relev although serum level may
use screen therapi respons tumor marker indic presenc msln-express tumor cell
msln-target t-cell clinic trial upenn patient pancreat cancer stabl diseas complet
three week intraven t-cell therapi decreas maximum standard uptak valu seen transient
site diseas therapi sustain repeat imag analysi ascit fluid day three
post reveal decreas concentr tumor cell co-express msln c-met given
studi express transient mrna electropor cell cautionari measur use mous
hybridoma-deriv scfv could elimin endogen immun reaction transient tumor respons
encourag set stage altern cell engag abil repeat dose viabl impact
identif envis combin treg deplet strategi might becom relev path
forward pancreat ductal adenocarcinoma pdac note simultan explor ovarian cancer
poc data indic anticip estim deeper dive refer page
enter crowd bcma field inher advantag tritac ts could allow easier
combin standard care earlier line novemb harpoon grant rate
option licens world-wide right bcma-target tritac treatment multipl myeloma like
initi patient phase studi clinicaltri gov identifi financi implic
elabor upon page note recent hiccup produc orr
vgpr pr respect could underli driver expand focu tritac
encompass treatment multipl myeloma note target express
multipl myeloma cell highlight page preliminari orr meaning subpar compar
bcma-target cell bispecif given genom instabl clonal heterogen mm give rise drug
resist result poor outcom continu augment therapeut arsen like theme
henc add new dimens abil supplant cell move treatment algorithm
combin either proteasom inhibitor immunomodulatori agent view
valuat risk invest thesi price target share harpoon deriv
year dcf-base sum-of-the-part analysi dcf driven beta termin growth rate risk premium
calcul wacc tax rate begin price target primarili leverag
outcom mcrpc oc pdac togeth repres approxim rnpv
 per share make roughli valu remaind deriv probability-adjust
mileston plu collabor revenu estim probabl pipelin
oc pdac target bcma express r/rmm patient
futur mileston associ collabor harpoon clinical-stag compani develop novel
platform cell engag tritac approv medicin henc risk target includ clinic failur either
due untoward safeti incid outright inabl demonstr clinic benefit manufactur challeng regulatori
challeng reimburs headwind commerci uptak along gener market financ risk
tabl content
compani overview drug pipelin
buy thesi harpoon predic upon modular tritac platform comparison vs bite threshold
iv valuat analysi financi outlook
assign po rnpv weight contribut
dcf encompass asset valu harpoon
licens deal tritac platform
 lesson tritac cell exhaust drawn construct bite-lik architectur
tox tumor uptak tumor microenviron
vii target psma mcrpc overview cell therapi mcrpc cell infiltr tumor creat hospit
environ introduct current dose escal studi
viii overview mesothelin viabl immunotherapi otherwis hard-to-treat solid tumor
ix overview bcma
 patient model psma mcrpc msln oc msln pc bcma
xi commerci financi model
harpoon south san francisco ca-bas clinical-stag immunotherapi compani develop novel class cell engag tritac
harpoon began trade februari subsequ price ipo
harpoon lead clinical-stag tritac current dose escal expans program treatment metastat
castration-resist prostat cancer mcrpc poc activ data anticip
oharpoon advanc second tritac clinic develop treatment ovarian cancer mesothelin msln
express solid tumor like pancreat ductal adenocarcinoma pdac
oon novemb harpoon expand clinic collabor rate elabor upon subsequ
harpoon grant option world-wide exclus licens target cell matur antigen bcma
expect enter clinic develop
tritac cell engag direct constant region complex tumor-associ antigen taa physiolog
condit cell direct cytotox activ toward cell express major histocompat class mhc molecul load epitop
recogn cell receptor tcr cancer cell mani mechan escap immun surveil among mani
relat antigen process present context mhc molecul bypass normal tcr-mhc interact
trigger cell activ tritac pois demonstr two benefit elicit polyclon cell respons affect escap
mechan involv downregul antigen present remark similar bite one strike differ
hour half-lif tritac vs hour bite translat conveni weekli dose former oppos
continu infus presenc target tumor associ antigen taa ideal limit normal tissu express
prerequisit tritac bispecif tunabl taa affin potenti workaround indic taa entir
restrict tumor cell addit cytotox fulli activ cell display rang cellular respons prolifer secret
cytokin case nave cell differenti establish activ differ effector function follow
hierarch organ depend differ variabl like intens tcr signal affin tcr cognat antigen
receptor occup sinc panopli cellular respons trigger simultan differ threshold cell
activ cytotox function requir less tcr stimul releas cytokin exist possibl fine tune
tritac cell engag capabl activ cytolyt activ cell without induc pronounc cytokin releas respons
note public trade compani rate
poc
pancreat mesothelioma
dose escal data expect provid color
activ event rate grade durat along
abil amelior step dose
mesothelin area activ interest given
wide case tumor specif express
howev given inher challeng solid tumor
vs ts target therapeut relev
dose challeng henc activ
tritac could signific valid view
post clinicaltri gov
enrol
mileston
pois becom fourth clinic stage candid
three wholly-own moa valid
predecessor posit impact
compani disclosur wainwright co estim
buy thesi harpoon predic upon
modular tritac platform
threshold cell activ
thought affin antigen densiti
thought valency/affin
tritac new class cell engag compos
bind domain link human serum albumin bind domain
link target-specif bind domain see diagram right
tritac share similar bite lack fc
compon substanti longer half-lif stem
hsa compon allow conveni weekli dose
oppos continu infus requir bite
nhp studi indic half-lif confer hsa
bind domain tritac substanti longer two
hour half-lif associ blinatumomab longer half-lif need
balanc potenti crs-relat trae consid
median onset blinatumomab treatment one day
howev use step-dos intend phase studi
implement across bite-lik format
exampl flotetuzumab could reduc grade intens
opinion
tritac platform develop iter process
allow biolog guid develop hsa linker
optim function effect numer tumor target
domain allow modular abil easili switch
tumor-target domain individu tritac differ tumor
target domain rest construct remain
allow predict pharmacokinet decreas risk
idiosyncrat safeti issu could facilit rapid discoveri
develop new product candid
like number factor includ limit antigen densiti affin affin tumor associ
protein antigen size distanc epitop membran interrel unfortun hierarchi import
yet discern best knowledg howev gener observ made
complex multi-subunit assembl compos either heterodim associ one
heterodim one heterodim two chain
oon oper model point like moa bispecif henc extens tritac permiss geometri model
propos full activ requir cluster spatial rearrang chain potenti valid observ
suggest activ non-activ antibodi bound differ epitop differ spatial orient
oaltern kinet segreg model cell activ postul interact cell target cell close
apposit two membran exclud bulki extracellular domain phosphatas synaps permit phosphoryl
tcr associ protein maintain lead signal transduct
onot effort ration design bispecif cell engag mani multival ab format engin improv potenc
tumor select tend depart natur architectur igg
othi turn potenti increas immunogen best knowledg immunogen clinic find
threshold cell activ
cytotox respons cell mediat tcr-mhc-peptid interact depend densiti
therefor expect cytotox induc cell engag tce follow similar depend howev
minimum copi number requir induc effect cell kill respons rang variat antigen
densiti lead signific modif cell kill activ like differ individu cell engag
henc activ psma-target tritac could differ mesothelin-target tritac view
histori cell engag could serv model exampl analysi effect antigen densiti
potenc cell engag shown differ result differ molecul bispecif ephrin type-a
receptor demonstr posit correl antigen express potenc ng/ml
ng/ml antigen express vari rang molecul per cell much lower impact
observ bispecif psma variat rang pm pm target
express molecul per cell effect target express potenc observ
bispecif mcsp
note similarli observ report igg-lik cell engag activ bispecif
correl taa densiti bispecif activ independ antigen densiti altern
explan discern vitro experi cell set wherein minimum
express requir induc substanti kill background molecul per cell
molecul requir obtain half-maximum lysi maximum lysi observ express molecul
per cell case explor cell express per cell would shown strong
correl copi number efficaci redirect cell kill
bottom line case cell engag lack correl antigen express potenc could
indic potent molecul requir minim target express support effect cell kill
thought affin antigen densiti
bispecif direct target low abund requir extrem high potenc effect bispecif ab
mimic tcr increas affin target greatli improv potenc
case target express higher level increas affin target gener improv potenc exampl
affin matur dart-fc p- cadherin nm nm improv cell kill potenc approxim
affin also enhanc via avid antibodi format multival exampl trimerbodi single-domain
ab fuse human collagen xviii trimer domain tumor antigen fuse scfv exploit multival
toward target increas function affin fold higher potenc vitro kill assay compar similar
format monoval antigen may option tritac view
one ab format fit gener trend greater vitro potenc higher affin toward target arm bispecif
report bispecif variou antigen show weak correl two paramet
potenti strategi evalu cell set could relev tritac bispecif
oepitop select fine-tun tumor cell select case antigen finit express normal tissu
omodul affin taa mean discrimin cancer cell normal tissu
case former cell kill activ cell target distal intermedi domain either normal cell
three differ cell line express higher copi number rang copi per cell normal cell
copi per cell evalu car-t cell direct intermedi domain domain exhibit
effici lysi cell line lysi normal cell undetect
regard taa affin modul set construct affin rang nm nm
evalu panel cell line express differ level cell construct lower affin
rang nm nm effici elimin cell express high level spare lower
thought valenc affin
prevent potenti cell activ absenc target engag cell engag ab format monoval
howev univers featur ab format bival advanc clinic
exampl tandab bival target antigen cell studi done specif address potenti
antigen-independ activ cell led cell activ cytokin releas presenc cell
howev preserv monoval bind prefer thu modif affin restrict affin matur use
avid strategi gain affin reflect tritac
note literatur review suggest lack correl bind affin cell activ potenti appear support
product hit rate model cell activ activ tcr interact mhc-peptid complex absolut
affin determin effici cell activ rather turnov product tcr-mhc-peptid complex greatli influenc
rate associ
potenti advantag ab reduc bind affin retain abil trigger cytotox could translat improv pk
biodistribut safeti contribut direct ab tumor rather circul cell gener trend cell engag like tritac
design monoval bind lower affin taa promot distribut tumor also reason relat
safeti
recruit cell besid trigger cytotox target cell induc releas cytokin excess lead high-grad
class effect limit therapeut index least tumor-specif taa limit express normal tissu inde report
reduc potenc bispecif begin separ rel threshold cytotox cytokin releas
henc affin like depend format taa affin beyond therapeut index numer consider favor reduced-pot
taa broad express target normal cell lead pronounc antigen sink via target-medi drug disposit lead
nonlinear pk poor unpredict exposur bispecif reduc potenc administ higher dose level overcom
antigen sink provid superior exposur case shed antigen caus direct sequestr drug overcom
higher dose accommod lower-pot format taa affin also reduc case suggest program affin tune
taa-target arm may warrant creat ideal drug profil
comparison cell receptor complex across platform
classic type interact membran membran space rang nm
scfv-base car-t cell bind tumor antigen membran space rang nm
bite bind cell tumor antigen target cell bring target cell close proxim form cytolyt synaps
comparison redirect cell therapi
size molecul kda
like similar
antigen- experienc tn
hour
day month
like perforin
perforin granzym fas/fas-l
like mimic bite
passiv biodistribut depend
factor relat rate diffus
vascular endothelium fluid flow
rate interact target
activ traffick cell involv
interact variou molecul
day design center
control
tce minim compos cell bind compon
bind domain tumor associ antigen taa bind domain
includ bite tritac upon infus bispecif simultan
bind taa bispecif form bridg two
independ mhci express
taa activ tcr
costimulatori domain cell mechan cell engag
downregul mhc-i loss intracellular peptid transport
short circuit antigen present
tce induc apoptosi low antigen express
bispecif necessari form small cytolyt synaps
cell target cell perforin granzym b-fill
vesicl secret target cell thu amount taa
express requir bispecif activ much lower requir
reliant upon fc
domain antibodi stimul cell mhci express antigen
upon releas granzym perforin target cell caspas
activ parp cleavag dna fragment occur ultim
lead apoptosi
bind affin bispecif limit factor
bispecif activ cell engag may mediocr affin
psma affin nm mesothelin nm
tumor kill activ order picomolar affin
cooper follow bind cell engag thu
bind affin less import find good epitop allow
activ
low level antigen express treatment
picomoloar activ reflect mechan distinct adcc
drastic differ efficaci may primarili reflect fact cell
recruit activ much potent effector
cell natur killer
nk cell monocyt macrophag
granulocyt recruit activ via fc portion human
immunolog review journal cancer
iv valuat analysi financi outlook
assign probabl success po rnpv risk adjust npv weight contribut
dcf encompass asset valu harpoon
licens deal tritac platform
assign probabl success rnpv
repres rnpv
probabl
psma valid target mcrpc
tritac half-lif address defici first-gen bite
continu invest psma bispecif add credenc
ada date
use step-dos like mitig worri potenti
allow immun system mount forc respons
poc potenti could support signific upsid
wholly-own asset
msln overexpress roughli oc play key role
metastasi
phase trial initi april poc
licens
msln overexpress pdac
phase trial initi april poc
howev given inher challeng
target pdac use
wealth data across cell bispecif adc along
anticip near term approv posit bcma excel
target mm
given competit natur landscap poc data
year use nomin po
po reflect development regulatori mileston
includ futur commerci mileston overal repres
rnpv recal fulli consumm partnership could net excess
harpoon sharehold refer page
hcw estim launch market penetr
market size sale estim
launch price
size
risk-adjust npv captur
reflect mani indic harpoon like pursu
weight contribut across geographi
encompass
valu harpoon
discount beta rate yr premium equiti debt growth valu total non-cash work cash flow valu cash per inc
anticip oper loss respect
harpoon exit approxim pro forma cash equival suffici fund
oper assum collabor relat mileston note harpoon amend licens
agreement announc novemb would allow near-term mileston payment reflect
although compani financi well posit near term model assum addit capit rais
share fund rapidli grow clinic pipelin corpor activ
relev wholly-own octob novarti nv rate announc acquisit endocyt
cash roughli premium close endocyt stock price day prior note
endocyt lead asset phase highlight import psma target mcrpc set
point floor valuat plan expans studi demonstr robust activ view
quick look burn period cash total cash cash period cash yr qs qs qs qs yr qs qs qs qs yr inc
addit target
rate collabor agreement develop commerci six preclin program
option global licens right util harpoon tritac technolog
up-front fee plu addit select four new target six total
mileston includ
develop regulatori commerci mileston licens
entitl receiv tier mid-singl digit percentag royalti world-wide
up-front fee
conting near-term cash mileston payment upon first patient dose
option exercis fee
follow option exercis aggreg mileston includ
develop regulatori commerci mileston product
entitl receiv tier rang high singl digit low doubl digit percentag royalti world-wide
harpoon file novemb
 lesson tritac cell exhaust
drawn construct bite-lik architectur albeit
leukemia lymphoma
tce-induc cell activ depend target antigen bind
bispecif exclus bind
human version epcam evidenc
lyse cho cell express human murin epcam see
ad cultur pbmc
sourc cell cho cell express either human
murin epcam cultur human epcam
induct marker cell activ cell see
similarli presenc human epcam cell
secret cytokin ifn tnf see top right
data suggest bispecif may bind
domain cell activ cell
bind target antigen decreas risk off-target
toxic encount use antibody-drug conjug
journal immunotherapi doi
tce known induc cell exhaust
contrast vitro experi show addit bispecif could induc cell activ upon treatment blinatumomab sever exhaust
marker increas cell bone marrow sampl evalu six patient see
treatment blinatumomab induc signific upregul patient bone marrow cell non-signific increas
suggest weaken effect success bispecif infus hamper cell exhaust
substanti hypothesi bispecif could induc cell exhaust case studi patient refractori blinatumomab report
combin treatment antibodi induc inflammatori respons reduc bone marrow blast indic
similar data report flotetuzumab buy context aml see subsequ slide could ramif
harpoon tritac view
respons flotetuzumab predict baselin tumor immunogen
thirti patient refractori relaps aml evalu
abund variou cell type gene express chang
cytokin abund tumor state see heat map
subsequ treat flotetuzumab non fc-
bispecif order determin correl exist
tumor microenviron patient respons
classif either immune-infiltr immunedeplet
base gene signatur bone-marrow sampl
accord system immune-deplet patient
non-respond
immune-infiltr patient
increas ifn- express
increas myeloid cell abund macrophag neutrophil
present dr rutella
rational combin checkpoint inhibitor
present dr rutella cancer immunol immunoth
thirti patient refractori relaps aml treat
flotetuzumab bone marrow sampl evalu
pre- post-treat
ifn- ifn-
continu increas would normal consid
posit continu express ifn- translat increas
express see left result consist
examin circul ifn- express
aml blast shown
induct ifn- support vitro studi
express multipl aml leukem blast
cell line measur incub ifn-
ifn- incub induc two-fold increas
express five eight cell line examin
separ studi relaps aml patient treat
flotetuzumab found higher express patient bone
marrow blast see right suggest cytotox ifn-
express caus tumor react promot
express enhanc likelihood relaps
examin effect combin
therapi flotetuzmab incub aml cell
line low
effector cell ratio either
viabil aml cell measur
treatment flotetuzumab alon reduc aml cell viabil
combin antibodi
reduc viabil respect
experi show capac aml blast rapid
inactiv cell util block mechan
disrupt interact
macrogen poster present
bite activ enhanc cell stimul
lysi capabl
bispecif cell engag
blinatumomab evalu vitro
conjunct vari level cell activ induc
pbmc either untreat treat briefli pbmc
treat four day lak-cel
incub blincyto target cell
brief treatment enhanc cytotox effect
blinatumomab extend treatment significantli
enhanc pbmc blincyto cytolyt capabl
activ state cell enact cytolyt activ
bispecif highli depend
journal cancer
treg determin respons blinatumomab
studi patient treat blinatumomab percent treg present patient
bone marrow prior treatment analyz respond non-respond
patient fewer treg gener better
respons
blinatumomab suggest treg bm could threshold respons consid
respond fewer treg non-respond greater treg
respons analysi
effect blinatumomab treg cell sampl healthi donor
patient test vitro treatment blinatumomab ab hour subsequ
evalu chang cytokin profil see top panel treatment blinatumomab result
increas cytokin product treg form tnfa ifn-g
data indic presenc treg predispos patient toward respons use
bispecif clearli bispecif activ depend tme
dexametheson vitro reduc cytokin releas lysi
ad cultur
contain pbmc healthi donor cell
express effect dexamethason
addit induc secret cytokin ifn tnf il-
suppress dexamethason see top
larg reduct cytokin suppress like due
fewer activ cell dexamethason small effect
importantli reduct cytokin appear
effect amount rate lysi target cell assess
four patient pbmc two shown bottom panel
vitro data support use dexamethason clinic
studi reduc excess cytokin releas without compromis
lytic activ activ pbmc cell
dexametheson reduc follow bispecif treatment human
dose-escal phase studi
administ dexamethason conjunct
significantli reduc
addit pk paramet medi-
diminish upon treatment
step-dos mitig bispecific-induc nhp
cynomolg monkey dose
bispecif develop
solid tumor date indic
black arrow use either singl
bolu step-dos regimen
evalu cytokin respons
dose protocol level tnf-
never rais pre-dos level
even sever sequenti dose
g/kg contrast singl dose
g/kg caus spike tnf-
reach baselin level
respons
bispecif even
rais
baselin level still
dose g/kg level boost
sever cytokin could reduc
risk
toxicolog appli pharmacolog
flotetuzumab bispecif dart develop treatment aml
mitig event flotetuzumab evalu vari lead-in-dos lid regimen rang
shown chart left
extend lid via multi-step intervent reduc averag grade week evalu
averag grade improv multi-step lid vs two single-step lid
phase dose-escal studi blinatumomab
frequent treatment-rel event neurolog event
neurolog event dose limit frequent
caus discontinu
neurolog event like due cytokine-releas
cell migrat
use dexamethason prophylaxi recommend routin
treatment manag
respons
interrupt follow reinstitut dose escal
recommend step includ dose
journal clinic oncolog blincyto
vi consider tritac
cell anti-drug antibodi on-target off-tumor
tox tumor uptak tumor microenviron
bite activ depend cell
depend cell donor sourc
capabl
evalu vitro
bispecif cell engag blinatumomab
cell
increas concentr blinatumomab inocul
cultur constant ratio cell cell
use cell obtain six donor see top
among six cell donor signific variat
rang ng/ml ng/ml maxim lysi
rang see top
broader evalu depend cell sourc
lytic activ perform evalu
signific variabl observ
sampl produc valu cell lysi
pg/ml peak pg/ml pm
approxim donor cell exhibit valu
pg/ml pm variabl could explain natur
variat cell activ exhaust
thu signific variabl cell direct lysi
singl sub-picomolar rang ensur activ within
rang normal cell function
journal cancer
upon initi chronic iv infus blinatumomab dose
transient decreas cell
observ occur within first day attribut
redistribut cell peripher blood presum
tumor site see top degre cell nadir
posit correl initi dose
recoveri serum cell baselin level occur
mean day patient expans
baselin level observ
cytokin releas peak day one return baselin
day two multipl dose induc toler blinatumomab
bispecif
evalu phase studi metastat sponsor
aptevo apvo rate
initi cohort patient mcrpc patient
treat weekli iv develop high
titer anti-drug antibodi ada caus rapid
switch continu infus two later cohort result
patient develop ada lower titer
drug detect serum howev
approach
ultim unsuccess discontinu due
sourc ada could link
null fc region present
verifi note
fc region
bispecif induc anti-drug antibodi patient
five patient high titer ng/ml result
decreas concentr two patient treat
follow-up clinic studi administ
continu iv although result better
mainten steadi state drug level also induc ada
patient treat dose mg concomit drop drug
safeti profil accept immunogen lead
insuffici exposur object respons prompt
sponsor discontinu program
annal oncolog
restrict tumor necess
solitomab bispecif administ
patient relapsed/refractori solid tumor dose
escal studi dose rang g/d
benefit reach g/d wherea preclin
studi indic therapeut benefit could reach g/d
redistribut cell observ immedi follow
administr see top cytokin induct evid
sever dose schedul regimen see middl
approxim patient withdrew studi due
withdraw consent non-compli death twelv
patient experienc dlt either liver enzym elev
diarrhea diarrhea seen preclin model sever
durat treatment refractori natur unforeseen
sever diarrhea attribut origin duodenum
consist tissu express pattern epcam
thu examin antigen express could predict off-target
effect reinforc potenc bispecif necess
antigen express exclus tumor note examin
tissu express harpoon target subsequ
 wainwright co research journal clinic oncolog may oncoimmunolog
doi mol cell proteom doi
tumor antigen express
concern expect preclin
result physiolog csf serum ratio igg antibodi
around still permeabl henc antigen bind
site could compet peripher site though
patient inject mab
extracellular matrix antigen tenascin amount antibodi
present cns-locat glioblastoma compar blood
concentr analyz averag tumor local
box red rang approxim
note mab typic size kda use
wherea tritac smaller kda thu could transit
bbb eas view
result indic antigen without peripher
express possibl activ exist low due
reduct effect drug concentr nearli
base genome-wid transcriptom antibody-bas
express psma bcma
wherea quit
msln minim
develop
page
tissu express target antigen
use classifi tissue-
specif express variou gene
sampl collect
healthi individu tissu
shown absolut level
rna detect indic tissu
tissu highest express
antigen darken
color lower express
tissu lighter
upregul malign
psma bcma
reflect chart chart
show possibl off-target
mab rare cross bbb
patient nhl treat mab rituximab receiv sever infus cours month
plasma csf concentr rituximab measur
compar plasma csf concentr rtixumab csf level mirror plasma mute fashion peak csf
concentr reach g/ml day approxim level plasma timepoint
treatment suffici reduc cell less plasma effect undetect csf
thu larg recombin protein may cross bbb small amount unlik accumul suffici concentr affect
slow intern small size deep tumor penetr
sever combin
variabl domain adc typic igg antibodi
evalu tumor penetr clearanc effect
anti-tumor activ
use tumor spheroid made cell
construct evalu depth penetr multipl
experi see graph distanc edg
intern half-lif see tabl right correl
depth
tumor penetr slowest
internatl half-lif min greatest
penetr beyond tumor edg
corollari rapidli intern biparatop construct
deepli penetr tumor
like intern cell near surfac trap
adc layer slower intern construct time
diffus interior
effect molecular weight obviou inabl
slower intern mab deepli penetr despit
slowest intern kinet
thu tritac kda size third smaller
continu next page
domain affin
psma
domain affin
second
epitop psma
slow intern small size deep tumor penetr
greater tumor penetr smaller
molecul result greater fraction
cell target tumor see
graph left
intern highest
still deliv durabl
respons psma tumor
examin highlight limit
larg molecul drug deliveri vehicl
solid tumor
intern caus sequestr
molecul superfici layer tumor
greater
tumor penetr
compens lower potenc
caveat
vii target psma mcrpc overview cell therapi
mcrpc cell infiltr prostat tumor introduct
current dose escal studi
psma taa valid target prostat cancer
journal immunotherapi cancer
psma intern rate increas bound anti-psma antibodi
psma express increas cancer progress
psma neg regul androgen receptor therefor increas upon androgen-
depriv therapi typic first-lin treatment prostat cancer
comparison drug modal use prostat cancer
size molecul kda
day
difficulti
grade ae
declin
note public compani includ novarti nv rate bayer bayri rate sanofi sni rate progen rate
lancet oncol volum issu june page journal clinic oncolog suppl may lancet
prostat journal clinic oncolog may journal clinic oncolog suppl
march journal clinic oncolog suppl march
cell activ prostat cancer requir immun stimul via
studi five patient treat psma-target autolog ts
respons strongli correl plasma see tabl
infus
patient lymphodeplet flu/ci
autolog psma-car cell began low-dos proleukin
continu infus week
plasma level monitor patient achiev high
level reach target rang iu/ml dose
scheme patient low level
inhibitor detect rather propos engraft
activ cell express caus deplet plasma
may starv tumor-kil cell
support graph right show invers relat plasma
engraft
dn-tgfr may modif need solid tumor activ
treatment anti-psma car-t cell
stimul evalu phase clinic trial seven mpca
patient result sd two
week persist cell circul though indic
present fever spike increas
psma-car therapi revamp ad tgfr-
domin neg protein progress phase studi
upenn follow administr patient follow
cell persist day cohort see graph
right
first two cohort report transient without dlt
respons howev first patient dose third cohort
show rapid decreas serum see next page
accompani grade may contribut
lethal septic infect
could come
lymphodeplet regimen implement
continu next page
journal clinic oncolog januari journal
clinic oncolog februari jan
dn-tgfr may modif need solid tumor activ
optim remain
rapid decreas posit signal
activ diseas regress
indic activ like limit
factor treatment
instead think focu growth
cell warrant increas cell
third cohort unlik typic trend
cell expans rather rapidli peak
slowli rapidli decreas cell continu
increas interpret
omin
uncontrol cell growth ts tri
combat creat
compani follow-up studi seek use split
dose manag follow-up cohort
would use lower infus manag
journal clinic oncolog januari journal clinic
oncolog februari jan present
takeaway peer experi mcrpc
treatment
taxan hormon therapi recommend first second-lin
landscap riddl failur
promis reduct come treatment
radiolabel small molecul clinic develop
bind psma enhanc bone uptak may prefer
patient boni metastas phase single-arm studi report
orr patient decreas
howev comparison cabazitaxel taxan like docetaxel taxane-
hormon therapy-experienc patient
median time
progress slightli better month actual
shorter median overal surviv treatment silver
line produc cr rate rare
mcrpc pr norm like consequ deep
tumor penetr possibl small molecul unlik larger
molecul like mab adc limit tumor penetr could
around kda mcrpc base report bite
induc complet regress soft-tissu tumor lesion novarti nv
rate expect present phase data
mcrpc nda file expect year
januari present outcom far clear
primari endpoint os approv base time
progress possibl would like opinion
think interest piec data come
bispecif short half-lif dose-escal
studi produc two durabl respons last longer median os
similar patient popul phase studi small
cohort detail respons given
potenti cell engag indic
hint
psma-target show anti-tumor activ mous
model deploy heavili pre-treat mcrpc patient
design provid longer exposur heavili protect tumor
extracellular matrix stroma howev
longer exposur
circul also allow hematolog problem neutropenia
aris eventu caus drug discontinu due
sepsi obstacl especi limit adc
biolog ts cell engag may undesir
clinic data psma-target car-t show high orr
small number patient due
improb deep tumor penetr prostat cancer
approach must engin durabl weak mani
approach numer indic effort enhanc
persist dose express dominant-neg
tgfr evalu clinic use mrna-induc transient
express cell immunogenically-mask allogen
cell could also impact
inhibitor evalu heavili pre-treat patient
demonstr limit respons probabl due
immunolog cold tumor outlook checkpoint inhibit
dampen fact express higher metastat lesion
primari site suggest primari site resist could
cell tumor infiltr like critic compon
effect tritac anti-tumor effect amount
exist tumor infiltr vari depend multipl factor
examin primari prostat tumor deriv
european african-american patient see tabl right
cell densiti measur cell per tissu
analysi found cell densiti non-significantli
associ race tumor progress vs gleason
score significantli neg associ
concentr though minor effect
thu clinic correl cell densiti appear
absent presenc cell cold tumor bode
well tritac activ could partial depend
intratumor presenc cell
design psma-target prostat cancer
closest compar
evalu patient phase studi due
short half-lif discontinu favor modifi version
report half-lif hour
monotherapi combin pembrolizumab phase
studi mcrpc patient modifi half-lif
bind psma unchang
therefor comparison pk cell cultur mous model
activ could predict later
comparison see tabl
import differ
former util fc domain wherea util
albumin-bind domain enhanc half-lif bispecif
use fc domain
induc anti-drug
antibodi induc ada phase
clinic data report best
pk profil show half-lif hour
significantli greater evalu
schedul on-going phase studi half-lif
greater excess long half-lif
could associ higher grade durat view
cell fold greater
four differ cell
line similar show
neglig activ psma neg cell line indic
may redirect cell activ effect
extens estim
detect
harpoon poster aacr annual meet journal clinic oncolog
suppl march
greater activ
consist greater vitro lysi rel
much potent mice elimin
tumor low dose g/kg compar similar activ
g/kg tumor
differ half-lif drug essenti
elimin once-daili dose drug begin
day day thu enhanc
potenc could reflect enhanc lytic activ rather
caveat comparison mice treat
treat later tumor grown
wherea mice treat treat
tumor
 wainwright co research adapt harpoon poster
transient nhp indic activ
transient declin cell nk cell
monocyt follow initi dose
nhp becom toler fourth dose
smaller declin circul cell see right
like evid direct cell
transient dose-depend increas
ifn- note treatment nhp
see bottom
harpoon poster aacr annual meet
progress dose escal expect pk
indic immun activ
dose escal begun august handl
prior
dose escal progress measur pace due
appear issu earli manag
mainstay across multipl hematolog malign across
redirect cell engag platform view headwind
futur commerci adopt assum robust activ
initi patient evalu indic expect pk anim
studi suffici half-lif weekli dose
anti-drug antibodi detect
next step follow dose escal expans studi
manag indic could occur prior reach
term rate dose escal program
fda give leeway design time requir
howev accumul manag experi
timelin later candid
dose escal plan dose one patient per cohort
dose increas cohort cohort ae trigger
expans dose increas
patient mix rout progress like confound direct comparison
dose escal segment
baselin expect potenti
higher base superior
vivo pk data
dose escal program among
patient treat
reduct two
patient durabl respons extend
month
clinic experi
serv anoth potenti benchmark
among patient treat fraction
dose approxim half phase
dose exhibit reduct
median overal surviv
like patient lightli
treat patient receiv prior
cross trial comparison dose escal
set like complic rout diseas
progress radiograph imag
baselin characterist exposur prior
grade ae
grade ae
declin
journal clinic oncolog may cancer
hurdl expans cohort
enrol expans cohort expect initi
experi similar set highlight
declin patient see tabl right note
reduct may insuffici stand-alone metric
durat drop also import could signal
pivot phase studi vision
initi april novarti plan submit
os primari object could gain
approv base secondari object radiograph
anti-androgen evalu efficaci use time
progress would even earlier
radiograph
unmet clinic need high indic rapid
enrol person studi accomplish less one
grade ae
grade ae
declin
viabl immunotherapi otherwis hard-to-treat solid tumor
viii overview mesothelin
mesothelin glycoprotein common cell-surfac
antigen found mesothelioma ovarian cancer pancreat
although commonli membrane-bound gpi-link protein
extracellular domain mesothelin shed tumor cell
detect serum mesothelin may use dx
mesothelin thought contribut cell adhes differenti
signal transduct cancer cell
overexpress cancer cell may promot prolifer cell
migrat spread chemotherapi resist inhibit
apoptosi activ multipl intracellular pathway
includ nf-b mapk pathway
bind mesothelin cancer antigen ca neoplast
set suggest role cell adhes potenti target
anti-cancer therapi particularli ovarian cancer
mesothelin implic promot periton metastas
msln express well elev serum smrp level
associ progress tumor burden increas stage
importantli mesothelin express normal cell limit
mesotheli cell line pleura
peritoneum
increas potenti therapi lower risk off-target
mesothelin relev target ovarian cancer
ovarian cancer antigen/biomark
msln
ligand could potenti mediat cell adhes exampl
interact mediat heterotyp cellular
addit msln bind specif n-link
tumor cell could bind specif mesothelin-express
n-link oligosaccharid necessari
bind msln msln strong affin
appar kd nm
play import role periton implant ovarian
initi attach ovarian cancer cell periton
mesothelium co-overexpress msln
lead recruit ovarian cancer cell
slough primari site
tumor
load secondari site could
combin excess prolifer adhes
circul singl multicellular aggreg periton ascit
msln activ shed cell surfac gener pool
antigen ascit blood circul allow
quantif circul serum msln level potenti
surrog marker tritac activ
transient express lower risk hint activ
patient chemo-refractori metastat pancreat ductal
adenocarcinoma treat three round three week
autolog cell transient express mesothelin-direct
note patient initi enrol four dose due
progress manufacturing/apheresi failur
use fdg-pet/ct imag tumor three patient exhibit diseas
stabil fourth patient reduct metastat
lesion though effect primari site see top left
measur use recist two patient qualifi stabl
diseas last month
mix respons seen could due differ
target antigen express reduc capac cell
effect infiltr primari lesion suppress tme
primari site
patient develop neurotox howev patient
tumor respons exhibit higher level releas see
top right fold increas larg indic effect
respons therapi may eventu induc low level
epitop spread evid sever patient see bottom left
greatest patient coincid greatest respons
transient natur express also prevent anti-
antibodi develop three patient see bottom right
eventu would preclud effect subsequ redos
note anti-mous antibodi detect
supplementari figur signal intensitypost-treat signal fold fold fold increasecrespons oxid stressregul lymphocyt activationregul mononuclear cell proliferationregul lymphocyt proliferationposit regul cell inc
human transient meso-car cell suppress ovarian tumor mice
group john hopkin develop system transfect cell
could complet within hour begin
leukapheresi product hand compar month-long process
normal requir lentiviral-transduc
compel
rather use mouse-deriv mesothelin bind antibodi
previou studi state goal avoid immunogen
patient treat mouse-deriv mesothelin antibodi develop
anti-mous antibodi anti-car antibodi howev re-inject
direct use murin antibodi induc
robust humor respons reduc activ
greater immunogen possibl use murine-deriv antigen
binder group develop human mesothelin-bind
vitro exhibit lytic capac murin deriv meso-
see top therefor repeatedli dose human could less
like induc anti-murin humor respons
thu potenti
mice bear hmeso-express ovarian tumor inject
carma-hmeso see bottom day appar least
carma-hmeso cell necessari suppress tumor growth
level tumor burden tumor cell inject hmeso
necessari rather simpli activ nonspecif cell
experi shown mice lower tumor burden tumor
cell inject could effect treat carma-hmeso cell
indic ratio effector tumor cell contribut outcom
transient natur express inher limit ma-
hmeso effect address mice inject multipl
time weekli interv see top improv viabil
multipl inject indic prolong tumor suppress
benefici aggress tumor mice use
nude mean lower level cell almost cell
evalu immunogenc repeat administr
test import administr rout mice inject
either intraperiton intraven ro carma-hmeso
cell surviv measur day see bottom
intraperiton rout produc surviv benefit like
tumor confin abdomen thu ip inject
tumor proxim iv inject requir extravas reach
tumor cell expos mous cell
could ablat infus product find could somewhat
artifici ovarian cancer metastas occur divers tissu
exclus peritoneum
case multipl rout
inject could warrant clinic studi
tumor microenviron tme like present uniqu challeng
thought pdac
pdac dens fibrou stroma along immunosuppress environ could hinder activ posit note immunohistochem
analysi resect normal pancrea pdac suggest infiltr cell infiltr tumor confer improv surviv patient
higher level cell infiltr unfortun enhanc immun cell infiltr may equat better respons
ofor exampl cell prone inactiv due intrins mechan activ without costimul express
inhibitori receptor
ofurthermor express inhibitor receptor expect outcom activ may limit abil cell
tumor pdac known directli express receptor cell may also becom deactiv extrins influenc
mainli cytokin produc treg mdsc
oincreas treg popul within tumor peripher associ decreas tumor grade surviv pdac treg
myeloid cell enrich pancreat tumor rel normal tissu treg aris subset thymocyt bypass neg
select thymu despit self-recognit nave cell peripheri differenti presenc cytokin
otreg suppress cell endogen cell multitud immun cell primarili secret inhibitori cytokin tgf-
one mechan pdac accumul treg upregul chemokin receptor type involv treg
home activ addit pdac directli secret tgf- therebi inhibit cell activ promot treg differenti
oth presenc macrophag tumor peripheri associ increas metastasi increas recurr rate decreas
surviv level circul mdsc correl pdac diseas stage presenc immunosuppress cell cytokin
challeng cell therapi
deplet treg may becom import aspect redirect cell therapi pdac
othi may achiev via precondit tradit agent cyclophosphamid and/or fludarabin novel approach
inhibit reduc treg accumul mice pdac also use treg deplet similar
combin cyclophosphamid monoclon antibodi enhanc vaccin efficaci pdac mous model
orosiglitazon significantli reduc pdac progress metastas mice limit earli mdsc intratumor treg accumul
provid rational combin rosiglitazon cell therapi treat pdac
oanoth intrigu combin cell therapi metformin increas number til protect
apoptosi exhaust mice metformin also associ improv surviv pdac patient
tme-rel consider
target psma prostat cancer highli reactiv
stromal environ promot immun cell inactiv ecm
remodel format new blood vessel serv
oncolog seminar origin investig volum issu
immun cell
patient prostat cancer exhibit higher level circul
deplet tumor microenviron nutrient tryptophan
arginin impair cell activ by-product
arginin deplet nitroic oxid produc inhibit mhc
ii express antigen-pres cell therebi inhibit
cell activ induc cell apoptosi
chemokin receptor act home beacon
mdsc locat tumor environ receptor
ligand shown support tumor growth
invas increas express correl
breast cancer cancer
patient prostat cancer also exhibit higher
level
circul treg healthi compar cancer
dendrit cell neutrophil
target mesothelin ovarian cancer oc tumor
includ malign cell stromal cell
oc cell epigenet reprogram surround cell
promot tumor growth surviv metastasi
mesothelin believ play role surviv prolifer
tumor progress adher mesothelin bind oc
biomark play role metastasi
low mutat burden recruit reg upregul
immun checkpoint protein contribut oc durabl
cell tumor microenviron tam
immunosuppress promot angiogenesi
migrat metastasi cancer basel sep
oc
oxid
phosphoryl rather glycolysi atyp cancer
lend
oxpho disrupt agent possibl novel
continu invest mesothelin viabl immunotherapi target
cluster differenti
mammalian target rapamycin mtor
mammalian target rapamycin mtor
note publicli trade compani mention includ bayer bayri rate maxcyt inc mxct ln rate inc rate bristol-my squibb
rate inc buy selvaraju roch hold ag rhhbi rate immunocellular therapeut ltd imuc rate selecta bioscienc selb rate
 wainwright co biomedtrack
ix overview bcma
enter mm fray poc support
bcma-target tritac partner
cusp patient phase program
view updat bristol-my
rate shot arm bispecif target mm
hitherto domin cell
bispecif tritac remain reliant patient cell
could depress patient multipl prior line
therapi off-the-shelf featur along abil repeat
dose could allow bispecif move up-front especi
combin establish standard care view
patient activ dose
g/day
psma mcrpc
msln oc
msln pc
bcma express r/rmm
satescrpc death per annual metastat popul penetr patient averag treatment monthli cost price growth rate sale us revenu probabl adjust us revenu eucrpc death per annual metastat popul penetr patient averag treatment monthli cost price growth rate sale eu revenu probabl adjust eu revenu total mcrpc revenu probabilti adjust mcrpc revenu inc
r/rmm satesr/r mm patient death per annual express popul penetr patient averag treatment monthli cost price growth rate gross sale royalti receiv us revenu probabl adjust us revenu eur/r mm patient death per annual express popul penetr patient averag treatment monthli cost price growth rate net sale royalti receiv eu revenu probabl adjust eu revenu total r/rmm revenu probabilti adjust r/rmm revenu inc
xi commerci financi model
thousand except per share data
collabor licens revenu
good sold
research develop
gener administr
total incom expens
loss incom tax
net unreal gain market secur
thousand except per share data
flow oper activ
depreci amort
net amort discount market secur
prepaid expens asset
net cash provid use oper activ
flow invest activ
purchas properti equip
purchas market secur
matur market secur
net cash provid use invest activ
flow financ activ
proce common stock net commisis
proce issuanc conver preferr stock net issu cost
proce issuanc common stock upon exercis stock option net
payment defer offer cost net
net cash provid use financ activ
net increas decreas cash/cash equival
 equival begin period
 equival end period
thousand except per share data
cash equival
prepaid expens current asset
properti equip net
liabil stockhold equiti
oper leas liabil net current portion
accumul comprehens incom
total liabil stockhold equiti
outlook ratio analysi enterpris valu
burn period cash oper
total cash cash equival
period cash remain
ebitda sale
return asset roa
return equiti roe
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc harp-u
rate price target histori inc mgnx-u
rate price target histori inc tcrr-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
debjit chattopadhyay earl desouza certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur harpoon
therapeut inc inc inc includ without limit option right warrant
futur long short posit
januari neither firm affili benefici class common equiti secur
inc inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens harpoon therapeut inc therapeut inc
invest bank servic within twelv month seek compens compani mention
report invest bank servic within three month follow public research report
firm affili receiv compens inc invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
 wainwright co llc manag co-manag public offer secur inc past
firm make market harpoon inc inc inc
date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
